Tetrofosmin ROTOP: Uses, Dosage & Side Effects

What Is Tetrofosmin ROTOP and What Is It Used For?

Tetrofosmin ROTOP is supplied as a sterile, lyophilized (freeze-dried) powder in a multidose vial. It contains the non-radioactive ligand tetrofosmin - chemically 6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane - together with stannous chloride dihydrate as a reducing agent, sodium D-gluconate as a transfer ligand and disodium sulfosalicylate as a stabiliser. In this form the kit has no imaging activity on its own; it is the precursor used by a licensed radiopharmacy to prepare the actual radiopharmaceutical.

The final medicine, technetium-99m tetrofosmin injection, is formed by adding a measured volume of sterile sodium pertechnetate (99mTc) eluate - obtained from a 99Mo/99mTc generator - into the vial. Unlike sestamibi, tetrofosmin labels efficiently at room temperature: after gentle inversion the reaction is complete in approximately 15 minutes, with no need for a boiling water bath. During this step the stannous ions reduce Tc(VII) to Tc(V), which then forms a stable lipophilic dioxocation, [99mTc(tetrofosmin)₂O₂]⁺. After radiochemical purity testing (typically by thin-layer chromatography), the ready-to-use solution is drawn into a shielded syringe and dispensed for patient administration.

Once injected intravenously, 99mTc-tetrofosmin distributes throughout the body according to regional blood flow. It is preferentially taken up by cells with strongly negative transmembrane potentials and abundant mitochondria, particularly the cardiomyocytes of the left ventricular wall. Approximately 1.2% of the injected activity localises in the myocardium at rest, with rapid clearance from blood and surrounding background tissues. The tracer emits gamma photons of 140 keV, which are ideal for detection by a modern gamma camera using either planar imaging, single-photon emission computed tomography (SPECT) or hybrid SPECT/CT. The combination of physiological targeting and tomographic image reconstruction allows physicians to visualise anatomy, perfusion and ventricular function simultaneously.

Tetrofosmin ROTOP is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and numerous other regulatory authorities worldwide for the following diagnostic indications:

• Myocardial perfusion imaging (MPI): 99mTc-tetrofosmin is used to detect and assess coronary artery disease (CAD), to localise regions of reversible or fixed perfusion abnormalities (ischaemia versus infarction) and to help stratify prognostic risk before and after percutaneous coronary intervention or coronary artery bypass grafting. The test is typically performed as a combined rest and stress study, with stress induced by treadmill or bicycle exercise or by pharmacological agents such as adenosine, dipyridamole or regadenoson.
• Assessment of myocardial viability: In patients with reduced left ventricular function, sestamibi-like tracers including tetrofosmin can demonstrate residual mitochondrial activity in regions with chronically reduced contraction (hibernating myocardium). Areas that take up tracer despite akinesia or dyskinesia may recover function after revascularisation, whereas non-viable scar shows minimal uptake.
• ECG-gated SPECT imaging of left ventricular function: When images are acquired with ECG gating, the data can be reconstructed into a cine loop that provides quantitative measurements of left ventricular ejection fraction (LVEF), end-diastolic and end-systolic volumes and regional wall motion - all from a single injection. This is particularly useful in the surveillance of cardiotoxic chemotherapy regimens and in patients being considered for implantable cardioverter-defibrillators or cardiac resynchronisation therapy.
• Risk stratification after acute coronary syndrome: Tetrofosmin SPECT performed in the days to weeks after an acute coronary syndrome helps determine residual ischaemia, infarct size and viability of the affected myocardium, all of which guide subsequent revascularisation and medical therapy.
• Adjunctive breast scintigraphy and oncology applications: Although less established than for sestamibi, 99mTc-tetrofosmin has been used in some centres for breast scintigraphy, parathyroid imaging and assessment of tumour multidrug resistance, but these are not part of the principal licensed indications and vary by country.

The clinical importance of myocardial perfusion imaging in modern cardiology cannot be overstated. International guidelines from the European Society of Cardiology (ESC), the American Heart Association (AHA) and the American College of Cardiology (ACC) all recognise SPECT MPI - performed with either tetrofosmin or sestamibi - as a class I or class IIa recommended investigation for the evaluation of patients with intermediate pre-test probability of obstructive coronary artery disease, for risk stratification after myocardial infarction and for serial monitoring of ventricular function in selected oncology patients.

What Should You Know Before Receiving Tetrofosmin ROTOP?

Contraindications

There are relatively few absolute contraindications to 99mTc-tetrofosmin itself, because the amount of active ingredient delivered is extremely small (typically less than 50 micrograms per dose). However, several situations require that the examination be deferred, replaced with an alternative or performed only with additional precautions.

• Hypersensitivity: Patients with a known hypersensitivity to tetrofosmin, to any of the excipients (stannous chloride dihydrate, sodium D-gluconate, disodium sulfosalicylate, sodium hydrogen carbonate) or to 99mTc-containing products should not receive Tetrofosmin ROTOP. Re-exposure after a previous anaphylactic or severe cutaneous reaction is contraindicated.
• Pregnancy (relative): The examination should not be performed during pregnancy unless it is clinically essential and no non-radiation alternative is available. If imaging is unavoidable, the lowest administered activity consistent with obtaining diagnostic-quality images should be used, and the procedure documented carefully.
• Severe pharmacological stress contraindications: When the tetrofosmin MPI is combined with pharmacological stress (dipyridamole, adenosine or regadenoson), the usual contraindications to those stress agents apply - including severe reactive airway disease with recent bronchospasm, high-grade atrioventricular block without a pacemaker, severe symptomatic hypotension and known hypersensitivity to the stress agent. Exercise stress testing has its own contraindications, including decompensated heart failure, unstable angina, severe symptomatic aortic stenosis, acute myocarditis and uncontrolled arrhythmia.

Warnings and Precautions

Before your examination, inform the nuclear medicine team about each of the following:

• Ionizing radiation: 99mTc-tetrofosmin exposes the patient and staff to ionizing radiation. The radiation dose is carefully justified on the basis of clinical indication and the principle of as low as reasonably achievable (ALARA). Modern SPECT/CT systems, weight-based dosing and stress-first protocols can substantially reduce the effective dose, particularly for younger patients in whom cumulative lifetime radiation exposure is a more important consideration.
• Severe hepatic or renal impairment: Excretion of 99mTc-tetrofosmin is roughly equally divided between hepatobiliary and urinary pathways, with about 40% of the activity excreted in urine and faeces over 48 hours. In severe hepatic impairment hepatobiliary clearance may be slowed, which can cause increased background activity over the inferior wall of the heart and reduce image quality. In severe renal impairment, urinary excretion is prolonged, leading to higher bladder and pelvic activity.
• Recent nuclear medicine or radiology examinations: Residual activity from other radiopharmaceuticals (for example, 99mTc bone scan, 18F-FDG PET) or recent administration of gastrointestinal contrast agents may interfere with image interpretation. An appropriate interval between studies should be planned and the request form should record any recent imaging.
• Unstable clinical status: Patients with unstable angina, recent myocardial infarction (within 2-4 days), decompensated heart failure, severe aortic stenosis, acute pericarditis or uncontrolled arrhythmia should not undergo exercise or pharmacological stress testing until the underlying condition has been stabilised. In these patients a rest perfusion study or cardiac MRI may be a safer initial investigation.
• Severe reactive airway disease: If the stress component of the MPI is pharmacological (adenosine, dipyridamole or regadenoson), patients with active bronchospasm or severe asthma/COPD may not be suitable candidates because these agents can provoke bronchoconstriction. Alternative stress strategies (regadenoson is generally better tolerated than dipyridamole in mild airways disease, but neither is appropriate for severe bronchospasm) or exercise stress should be considered.
• Left bundle branch block, paced rhythm or Wolff-Parkinson-White syndrome: In these patients, exercise-induced septal perfusion defects may occur as artefacts. Pharmacological vasodilator stress is usually preferred to improve diagnostic accuracy and avoid false-positive interpretations.
• Recent large meals or caffeine intake: For cardiac indications, food and caffeine can affect tracer biodistribution and blunt the response to pharmacological vasodilators. Follow the fasting and caffeine-avoidance instructions given by the nuclear medicine department.
• Diabetes mellitus: Insulin and glucose can shift cardiac substrate utilisation and modestly alter tracer uptake. Standardised pre-test meals and careful diabetes management protocols are followed in many departments to minimise variability.

Patient Preparation

Proper preparation is one of the most important determinants of image quality and therefore of diagnostic accuracy. The following requirements apply to most adult myocardial perfusion studies, although individual departments may specify additional or modified instructions:

• Fasting: Fast for at least 4-6 hours before injection to minimise splanchnic blood flow and reduce hepatobiliary background activity. Sips of water and essential oral medications are usually allowed.
• Caffeine and methylxanthines: Avoid coffee, tea, cola, energy drinks, chocolate, decaffeinated coffee (which still contains some caffeine) and theophylline-containing medications for at least 12-24 hours before pharmacological stress testing. These compounds antagonise adenosine, dipyridamole and regadenoson at the A2A receptor and can produce false-negative stress results.
• Medications: The referring physician will advise whether cardiac medications such as beta-blockers, calcium channel blockers and nitrates should be withheld. These are usually held for an exercise stress test (to allow an adequate heart-rate response) but not necessarily for vasodilator stress, where the question is often how the patient performs on their usual treatment. Bring a complete list of current medications, including over-the-counter products and herbal supplements.
• Clothing: Wear comfortable two-piece clothing without metal zips or buttons over the chest. Bring trainers or comfortable shoes if exercise stress testing is planned.
• Smoking: Refrain from smoking on the morning of the test. Nicotine causes coronary vasoconstriction that can interfere with both stress response and tracer biodistribution.

Pregnancy and Breastfeeding

If you are or might be pregnant, you must inform the nuclear medicine team before any radiopharmaceutical is administered. Diagnostic imaging with ionizing radiation is generally avoided during pregnancy because of potential harm to the developing fetus, including a small theoretical increase in childhood cancer risk. The fetal absorbed dose from a typical 99mTc-tetrofosmin study at maternal doses of 800-900 MBq is approximately 5-8 mGy in early pregnancy, which is well below the threshold (100 mGy) at which deterministic effects are recognised, but is not zero. When a tetrofosmin examination is clinically unavoidable (for example for evaluation of suspected acute coronary syndrome in a pregnant patient where echocardiography and cardiac MRI are inconclusive), the minimum administered activity consistent with obtaining a diagnostic study is used, hydration is encouraged to reduce bladder dose to the fetus, and the benefits and risks are documented in the patient record.

For breastfeeding mothers, breastfeeding should be interrupted for at least 4-12 hours after administration of 99mTc-tetrofosmin according to the EMA SmPC, with milk expressed during this interval discarded. The exact recommended interval differs between national guidelines: ICRP Publication 106 suggests no interruption is necessary for tetrofosmin, while many European departments adopt a precautionary 4-12 hour pause. Close contact with infants (for example holding for extended periods) should also be limited for the first few hours after injection, because 99mTc emits gamma radiation that can reach the infant.

Fertility is not known to be affected by the very small amounts of tetrofosmin or the short-lived radioisotope used. Nevertheless, radiation exposure of the gonads should be minimised wherever possible, particularly in younger patients and those who may later wish to conceive.

Children and Elderly

In paediatric patients, the administered activity of 99mTc-tetrofosmin is reduced proportionally to body weight according to the EANM Paediatric Dosage Card, and specific indications are uncommon outside of specialised centres. Most paediatric cardiac imaging is performed with echocardiography or cardiac MRI rather than nuclear scintigraphy, but tetrofosmin SPECT is occasionally used to evaluate Kawasaki disease coronary aneurysms, post-transplant rejection or congenital coronary anomalies. In elderly patients, no dose adjustment is required, but underlying cardiac, renal or musculoskeletal comorbidities often dictate the use of pharmacological stress rather than exercise.

Driving and Operating Machinery

99mTc-tetrofosmin itself does not impair alertness or reaction time. However, pharmacological stress agents and any sedatives that may be given can cause transient dizziness, hypotension, flushing or drowsiness for a short period after the test. It is usually recommended that patients arrange to be accompanied home after any stress test and avoid driving immediately afterwards, particularly if dipyridamole or regadenoson has been used.

How Does Tetrofosmin ROTOP Interact with Other Drugs?

Pharmacokinetic interactions with 99mTc-tetrofosmin itself are uncommon because the injected mass of tetrofosmin is tiny (less than 50 micrograms) and well below any threshold for hepatic enzyme induction or inhibition. Clinically important “interactions” are mostly physiological - that is, they affect the quality or interpretation of the image rather than the pharmacology of the tracer. It is essential to provide the nuclear medicine team with a complete current medication list, including over-the-counter products, herbal supplements and recent courses of treatment.

Major Interactions

Minor and Situational Interactions

Because withdrawal of cardiac medications can itself precipitate ischaemia, hypertensive crisis or rebound tachycardia, never stop or alter prescribed medications on your own initiative. All decisions about which drugs to hold before a tetrofosmin study are made by the referring cardiologist or nuclear medicine physician based on your individual risk profile and the specific clinical question to be answered by the scan.

What Is the Correct Dosage of Tetrofosmin ROTOP?

Because Tetrofosmin ROTOP is a diagnostic radiopharmaceutical, the “dose” is expressed as an administered activity in megabecquerels (MBq) or millicuries (mCi), not as a mass of active substance. The amount of tetrofosmin mass actually delivered is extremely small - in the low microgram range - and has no direct pharmacological action. The aim of dosing is to deliver sufficient photon counts for a diagnostic study while keeping the radiation exposure as low as reasonably achievable. Published ranges differ slightly between the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the FDA label and national regulatory authorities; each department maintains its own validated protocols.

Adults

Children

Paediatric dosing of 99mTc-tetrofosmin follows the EANM Paediatric Dosage Card, in which the administered activity is calculated from the reference adult activity multiplied by a weight-dependent coefficient. For a typical cardiac examination, the minimum recommended activity is 80 MBq, and the typical activity for a 20 kg child is approximately 80-150 MBq (2-4 mCi), with appropriate adjustments for very small or very large children. Paediatric examinations should be performed only in centres experienced in paediatric nuclear medicine, and alternative imaging (echocardiography, cardiac MRI) is usually considered first.

Elderly

No specific dose adjustment is required purely on the basis of age. Weight-based dosing, modern camera technology and careful selection of rest-only or stress-only protocols should be used to minimise radiation exposure in older adults. Baseline renal function and comorbidities (particularly chronic kidney disease, heart failure and chronic obstructive pulmonary disease) should be considered when planning the examination and choosing the stress modality. In patients aged over 80 years, exercise stress is often impractical and pharmacological stress with regadenoson is widely used because of its convenience and reasonable safety profile.

Kidney and Liver Impairment

No dose adjustment is required on the basis of kidney or liver function. However, in severe hepatic impairment hepatobiliary clearance is slowed, so delayed imaging or repeat imaging after a fatty meal or warm milk drink may be needed to clear gallbladder and bowel background activity from the inferior wall of the heart. In severe renal impairment urinary excretion is prolonged; increased bladder activity may affect pelvic images and should be mitigated by hydration and frequent voiding where possible.

Missed Dose

Tetrofosmin ROTOP is administered only once per examination under direct supervision of a nuclear medicine physician or technologist, so the concept of a “missed dose” does not apply. If an appointment is missed, a new appointment is scheduled and the radiopharmaceutical is prepared freshly on the day of the study, because the short half-life of 99mTc (6.02 hours) means that an unused dose rapidly decays and cannot simply be saved for later use.

Overdose

An overdose of radiation rather than of tetrofosmin itself is the main concern if an inadvertent overactivity is administered. Actions to reduce radiation exposure include encouraging oral or intravenous hydration and frequent voiding to accelerate urinary clearance, and encouraging gallbladder emptying with a fatty meal, warm milk or a cholecystokinin analogue to accelerate hepatobiliary clearance. There is no specific pharmacological antidote for the tetrofosmin molecule itself, as the administered mass is far too small to cause systemic toxicity. If an overdose is suspected, the radiation protection officer and medical physicist should be contacted immediately, and the absorbed dose to critical organs should be calculated from the actual administered activity.

How Tetrofosmin ROTOP Is Given

The final 99mTc-tetrofosmin injection is administered as a slow intravenous bolus into a peripheral vein, typically via an indwelling cannula. To reduce the risk of extravasation, the nuclear medicine technologist verifies cannula patency with a saline flush before the activity is injected, and observes the injection site carefully during administration. Extravasation of a radiopharmaceutical can cause local pain, prolonged imaging delay and, in extreme cases, tissue damage. After injection, patients are usually asked to drink plenty of fluids and to void frequently to reduce bladder and gonadal radiation dose.

For cardiac studies, a fatty meal or drink (for example milk, yogurt or a cheese sandwich) is often given between injection and imaging to promote gallbladder contraction and clear subdiaphragmatic activity that could obscure the inferior wall of the heart. Imaging begins once adequate clearance has occurred - this is typically 15-30 minutes after stress injection and 30-45 minutes after rest injection. Image acquisition itself takes between 10 and 25 minutes for an ECG-gated SPECT study, depending on the camera system, dose and patient size.

What Are the Side Effects of Tetrofosmin ROTOP?

Because the administered mass of tetrofosmin is very small (less than 50 micrograms), pharmacologically mediated side effects are infrequent. Most symptoms experienced during a 99mTc-tetrofosmin study are related to the stress component (exercise or pharmacological vasodilators) rather than to the tracer itself, or to the radiation dose, which is a small incremental risk that must be justified against the diagnostic benefit. The frequency categories below follow EMA conventions and are derived from the summary of product characteristics and post-marketing surveillance data accumulated since the original approval of tetrofosmin in 1993.

Frequencies of Reported Adverse Reactions

Radiation Exposure

The effective radiation dose delivered to an adult undergoing a typical 99mTc-tetrofosmin study ranges from approximately 2-4 mSv for a stress-only protocol with a modern CZT camera to approximately 7-9 mSv for a traditional one-day rest/stress protocol with a conventional Anger camera. For context, the average natural background radiation dose in many countries is 2-3 mSv per year, and a single chest CT delivers approximately 7 mSv. The lifetime attributable risk of cancer from a single diagnostic tetrofosmin study is small - on the order of 1 in 2,000 to 1 in 5,000 depending on age and sex - and must always be weighed against the diagnostic benefit, which often includes direct impact on therapy, revascularisation decisions and survival.

Organs receiving the highest absorbed dose include the gallbladder wall, upper and lower large intestine, urinary bladder wall and kidneys. Tetrofosmin shows somewhat faster hepatobiliary clearance than sestamibi, which slightly reduces hepatic and biliary doses while modestly increasing intestinal exposure. Hydration, frequent voiding and gallbladder-emptying meals all help to reduce these local doses. Modern imaging protocols, including weight-based dose reduction, stress-first approaches and dose-reducing CZT and SPECT/CT technology, continue to drive down patient exposure substantially below the figures given in older prescribing information.

How Should Tetrofosmin ROTOP Be Stored?

Storage and handling are the responsibility of the radiopharmacy and nuclear medicine department and are strictly governed by pharmaceutical, radiation protection and transport regulations. Patients will not encounter storage decisions directly; the information below is provided for completeness and to help patients understand what happens behind the scenes.

• Unopened kit: Store at 2-8°C in a dedicated pharmaceutical refrigerator (some formulations allow up to 25°C - always follow the label). Protect from light and do not freeze. Do not use after the expiry date printed on the vial label and outer carton.
• Reconstituted injection: After radiolabeling and quality control, store the solution at 15-25°C, protected from light and in a shielded container. Use within the validated shelf-life, which is typically up to 8-12 hours from reconstitution but may be shorter - always follow the product label and national pharmacopoeia requirements. The 99mTc decay rate (half-life 6.02 hours) practically limits the useful life of any prepared dose.
• Radiation protection: All handling takes place in a licensed radiopharmacy behind appropriate lead shielding (typically 2-3 cm of lead for 99mTc). Syringes are dispensed in shielded transport containers, and waste is stored in shielded bins until it has decayed to background levels (approximately 60 hours, or 10 half-lives) before disposal.
• Inspection: The reconstituted solution should appear clear and colourless to slightly yellow. Do not administer if particles, discoloration or damaged vials are observed. Radiochemical purity is confirmed by thin-layer chromatography or an equivalent method and must meet the SmPC threshold (typically > 90% as the desired complex) before patient administration.
• Waste disposal: Unused radiopharmaceutical and any contaminated materials are disposed of in accordance with national radiation protection regulations. Do not dispose of radiopharmaceuticals via household waste or wastewater; appropriate decay-in-storage and dedicated disposal procedures are mandatory.

What Does Tetrofosmin ROTOP Contain?

Active Substance

The active ingredient of the kit is tetrofosmin, a diphosphine compound with the chemical name 6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane (molecular formula C₁₈H₄₀O₄P₂, molecular weight 382.5 g/mol). Each vial typically contains 0.23 mg of the ligand, sufficient to produce multiple patient doses of 99mTc-tetrofosmin after reconstitution with a suitable volume of 99mTc-pertechnetate eluate. The exact amount of tetrofosmin delivered per patient is in the low microgram range and has no pharmacological activity by itself.

Inactive Ingredients (Excipients)

• Stannous chloride dihydrate - reducing agent that reduces Tc(VII) in pertechnetate to Tc(V) so that complex formation with tetrofosmin can occur
• Sodium D-gluconate - transfer ligand that initially binds the reduced technetium and then exchanges with tetrofosmin during the labeling reaction
• Sodium hydrogen carbonate - buffering agent that maintains the optimal pH for radiolabeling
• Disodium sulfosalicylate - stabilising agent that protects the complex from oxidation and improves long-term radiochemical stability

The kit does not contain preservatives, antimicrobials or colouring agents. It does not contain lactose, gluten or ingredients of animal origin, which makes it suitable for patients with relevant intolerances, vegans and those following strict religious dietary observances.

Appearance

Tetrofosmin ROTOP is supplied as a white to off-white lyophilized cake or powder in a multidose glass vial sealed with a rubber stopper and aluminium cap. After reconstitution with sodium pertechnetate (99mTc) the resulting technetium-99m tetrofosmin solution is a clear, colourless to slightly yellow liquid free of particulate matter, with a pH of approximately 7.5-9. Each package typically contains 5 multidose vials (the exact pack size may vary by country and supplier).

Radionuclide Added During Preparation

The radionuclide technetium-99m (99mTc) is added to the kit in the radiopharmacy as sterile sodium pertechnetate (99mTc) injection, eluted from a regulated 99Mo/99mTc generator. Technetium-99m decays by isomeric transition with a physical half-life of 6.02 hours, emitting a near-monoenergetic 140 keV gamma photon that is ideally suited to gamma camera imaging. The short half-life and favourable photon energy are the major reasons why 99mTc is the most widely used radionuclide in diagnostic nuclear medicine worldwide, accounting for around 85% of all nuclear medicine procedures globally.

Marketing Authorisation Holder and Manufacturer

Tetrofosmin ROTOP is marketed by ROTOP Pharmaka GmbH, a specialised radiopharmaceutical manufacturer based in Dresden, Germany. The original tetrofosmin product, branded as Myoview, was developed by Amersham International (later GE Healthcare) and approved in Europe in 1993 and in the United States in 1996; ROTOP Pharmaka subsequently developed and registered an independent tetrofosmin kit formulation that meets the relevant European Pharmacopoeia monograph for technetium (99mTc) tetrofosmin injection. All formulations of the radiopharmaceutical must meet identical pharmacopoeial quality, sterility, radiochemical purity and bacterial endotoxin specifications regardless of the supplier.